Alexza resubmits drug focus early, shares soar

<p>(Reuters) – <span>Alexza Pharmaceuticals Inc resubmitted</span> a selling focus for a anti-agitation diagnosis progressing than expected, promulgation a shares adult as many as 47 percent.</p>
<p> Alexza’s Adasuve, that delivers an comparison antipsychotic drug called loxapine by a company’s Staccato inhaler, was denied capitulation twice before, many recently in May.</p>
<p> “The marketplace was not looking for (the resubmission) utterly this early,” <span>JMP Securities analyst</span> <span>Charles Duncan</span> said.</p>
<p> Early final month, when a <span>U.S. Food and Drug Administration</span> denied capitulation to Adasuve, a association had pronounced that a issues lifted by a group were “readily addressable.”</p>
<p> The <span>FDA</span> had found certain deficiencies during a company’s <span>Mountain Vie...